Discontinued — last reported Q3 '25
TechnipFMC Accrued Litigation decreased by 3.7% to $56.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 0.5%, from $57.20M to $56.90M. Over 3 years (FY 2022 to FY 2025), Accrued Litigation shows a downward trend with a -20.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase indicates higher legal risk or the recognition of new settlement obligations, which can negatively impact earnings.
Accrued litigation represents the estimated liability for legal claims and settlements that are probable and estimable....
Highly specific to the company's legal environment; peers in the pharmaceutical industry often carry similar provisions.
accrued_litigation| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $70.00M | $70.00M | $70.00M | $70.00M | $70.00M | $116.70M | $70.00M | $55.90M | $57.00M | $57.70M | $54.40M | $51.30M | $58.90M | $49.40M | $57.20M | $59.20M | $65.40M | $59.10M | $56.90M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% | +66.7% | -40.0% | -20.1% | +2.0% | +1.2% | -5.7% | -5.7% | +14.8% | -16.1% | +15.8% | +3.5% | +10.5% | -9.6% | -3.7% |
| YoY Change | — | — | — | +0.0% | +0.0% | — | +0.0% | -20.1% | -18.6% | -50.6% | -22.3% | -8.2% | +3.3% | -14.4% | +5.1% | +15.4% | +11.0% | +19.6% | -0.5% |